CTOs on the Move

RainDance Technologies

www.raindancetech.com

 
RainDance Technologies, Inc. provides microdroplet-based solutions for single molecule and single cell analysis in the life sciences industry. The company’s RainStorm technology generates various discrete droplets that can encapsulate a single molecule, single cell, or reaction. It offers RDT 1000, a solution that amplifies genomic loci and leverages the sensitivity and specificity of polymerase chain reaction methodology; and ThunderStorm System, a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome. The company also provides research screening panels, including ASDSeq for autism spectrum disorder research; XSeq for human X-chromosome research; ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Independent Vets

Independent Vets provides relief veterinarians to animal hospitals.

De La Torre Orthotics and Prosthetics

De La Torre Orthotics and Prosthetics, Inc. is a Brookville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cactus Health Systems

Cactus Health Systems is a Guelph, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

POH Medical Center

POH Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. POH Medical Center is based in Pontiac, MI. You can find more information on POH Medical Center at www.pohmedical.org

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.